IPP Bureau
Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
By IPP Bureau - January 11, 2026
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
By IPP Bureau - January 11, 2026
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
By IPP Bureau - January 11, 2026
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
By IPP Bureau - January 11, 2026
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Prokaryotics and Basilea team up to tackle deadly fungal infections
By IPP Bureau - January 11, 2026
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
PAI Pharma acquires Nivagen to boost US injectable drug production
By IPP Bureau - January 11, 2026
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit
By IPP Bureau - January 10, 2026
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
AstraZeneca appoints Laura Colon as new President of Spain
By IPP Bureau - January 10, 2026
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Revvity and Lilly partner to accelerate AI drug discovery models
By IPP Bureau - January 10, 2026
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Shilpa Medicare aims for US approval of chemo nausea drug
By IPP Bureau - January 09, 2026
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
Granules Pharmaceuticals secures FDA tentative approval and 180-day exclusivity for Generic Dyanavel XR
By IPP Bureau - January 09, 2026
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
IMCD opens beauty, personal Care laboratory in California
By IPP Bureau - January 09, 2026
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
Alkem launches innovative hair growth support therapy kit
By IPP Bureau - January 09, 2026
The supplements are made using only vegetarian-sourced ingredients
GSK secures European nod for easier-to-use Shingrix prefilled syringe
By IPP Bureau - January 09, 2026
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
GSK reports breakthrough results in chronic hepatitis B trials
By IPP Bureau - January 09, 2026
